


## Summary of the Fiscal Year

### SALES

Consolidated sales increased by 9% to €12,336 million in 2008. Excellent organic growth of 8% was achieved, while acquisitions contributed 5% to growth. Currency translation effects reduced sales by 4%.

#### SALES BY REGION



### EARNINGS

Operating income (EBIT) adjusted for special items relating to the acquisition of APP Pharmaceuticals grew by 11% to €1,727 million (2007: €1,609 million). All the business segments contributed to this substantial growth.

in million €	2008	2007	Change	Change in constant currency
<b>EBIT, adjusted</b>	<b>1,727</b>	1,609	7%	11%
Net interest	-431	-368	-17%	-20%
Income taxes	-442	-448	1%	-3%
Minority interest	-404	-383	-5%	-10%
<b>Net income, adjusted</b>	<b>450</b>	410	10%	13%

- ▶ In North America, sales increased by 9% in constant currency due to a good organic growth of 5%. Net acquisitions contributed 4%.
- ▶ In Europe, sales grew by 14%, with organic sales contributing 9%.
- ▶ In emerging markets, strong organic growth rates continued, achieving 17% in Asia-Pacific and 18% in Latin America.
- ▶ Group net interest was €-431 million (2007: €-368 million). The change compared to the prior-year figure is mainly due to the financing of the APP acquisition.
- ▶ Net income before special items relating to the APP acquisition was €450 million, an excellent increase of 13%. Adjusted earnings per ordinary and preference share rose by 11%.